Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple inhalation treatment help COVID-19 patients breathe easier?

NCT ID NCT04469491

Disease control Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if inhaling a protein called interferon beta 1b can help hospitalized COVID-19 patients who need oxygen. The goal is to see if the treatment reduces the amount of oxygen they need over 15 days. The study includes 74 adults with confirmed COVID-19 who are on oxygen therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

74 people

The number who actually took part.

Started

Sep 2020

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old * Patient with laboratory-confirmed SARS-CoV-2 infection as determined by PCR \< 96 h (at initial diagnosis or persistent carriage \<96 h) * Hospitalized patient with COVID-19 requiring oxygen therapy And targeting in phase B : * Patients under oxygen therapy such as nasal cannula/mask or non-invasive ventilation with paO2/FiO2 \> 200 mmHg. * Patients hospitalized for less than 7 days. * Patients with symptoms for less than 10 days or RT-PCR (\<96h) with Cycle Treshold \< 25. * Social security coverage * signed informed consent (by patient or their legally authorized representative) Exclusion Criteria: * Hypersensitivity to natural or recombinant interferon-ß * Hypersensitivity to human albumin or mannitol * Recent suicide attempt * Decompensation of liver failure * age \< 18 years * Pregnant or nursing. * Patients managed on an outpatient basis (i.e. not initially hospitalized). * Parenteral IFN treatment. In periode B, addition of new exclusion criteria * Patients with kidney transplant * Immunocompromised patients * Patients with severe systemic disease constantly threatening their vital prognosis (ASA ≥ IV: e.g. severe ARF, advanced cancer pathology, recent myocardial IDM, severe valvular dysfunction, dependence on parenteral nutrition on central line, shock, sepsis, trauma, ...). * Patients in septic shock. * Patients with documented fungal infection. * Patients on mechanical ventilation. * Patients hospitalized for COVID-19 for more than 7 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID -19 Interferon Nebulization

Contacts and locations

Locations

  • CH Compiègne-Noyon

    Compiègne, 60200, France

  • CH d'Abbeville

    Abbeville, 80142, France

  • CH de Saint-Quentin

    Saint-Quentin, 02100, France

  • CH de Tourcoing

    Tourcoing, 59208, France

  • CH de l'Arrondissement de Montreuil-sur-mer

    Rang-du-Fliers, 62180, France

  • CH de valenciennes

    Valenciennes, 59322, France

  • CHU Amiens

    Amiens, 80480, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.